Simply Wall St.1d agoneutral
Iovance Biotherapeutics (IOVA) Q3 Earnings Sharpen Focus On Margin RecoveryNews
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
107last 24h
3127last 7d
512● bullish (7d)
311● bearish (7d)
227publishers
GuruFocus.com2d agoneutral
Iovance Biotherapeutics Inc (IOVA) (Q3 2026) Earnings Call Highlights: Record $122 Million ...MT Newswires5d agoneutral
UBS Adjusts Price Target on Iovance Biotherapeutics to $8 From $7, Maintains Neutral RatingStocktwits40d agoneutral
IOVA Stock Hits Over 2-Year Highs - Why Iovance Raised Its FY2026 Revenue OutlookSimply Wall St.85d agoneutral
Is Iovance Biotherapeutics (IOVA) Undervalued As Q2 Earnings Reaffirm Revenue Guidance?GuruFocus.com94d agoneutral
Iovance Biotherapeutics Inc (IOVA) (Q2 2026) Earnings Call Highlights: Record Revenue and ...Simply Wall St.99d agoneutral
Iovance Biotherapeutics (IOVA) Heads Into Earnings With Its T Cell Therapy Story And Valuation In Focus